AMAG Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences

AMAG Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences

LEXINGTON, Mass., Sept. 3, 2013 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc.
(Nasdaq:AMAG) today announced that William Heiden, AMAG's chief executive
officer, will participate in two upcoming investor conferences. The sessions
will include a brief company presentation followed by a question and answer
session, in which the company's business, strategy and growth prospects will
be discussed.

The sessions will take place as follows:

  *September 9, at 3:15 p.m. ET -- Morgan Stanley Global Healthcare
    Conference in New York City;
    and
  *September 11, at 2:20 p.m. ET -- Baird's 2013 Health Care Conference in
    New York City.

Live webcasts of the presentations will be accessible through the Investors
section of the company's website at www.amagpharma.com.Both webcasts will be
archived on the AMAG Pharmaceuticals, Inc. website for 30 days following the
conferences.

About AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company that markets
Feraheme® (ferumoxytol) Injection and MuGard® Mucoadhesive Oral Wound Rinse in
the United States. Along with driving organic growth of its products, AMAG
intends to expand its portfolio with additional commercial-stage specialty
products. The company is seeking complementary products that leverage the
company's commercial footprint and focus on hematology and oncology centers
and hospital infusion centers. For additional company information, please
visit www.amagpharma.com.

AMAG Pharmaceuticals and Feraheme are registered trademarks of AMAG
Pharmaceuticals, Inc.; MuGard is a registered trademark of Access
Pharmaceuticals, Inc.

CONTACT: AMAG Pharmaceuticals, Inc. contact:
         Amy Sullivan, 617-498-3303
 
Press spacebar to pause and continue. Press esc to stop.